Bicyclic Compounds Inhibit HBV and HDV Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections do not cure the diseases, instead they only suppress the replication of the viruses, and there is no cure or vaccine available for HDV, leading to severe complications and high fatality rates, especially when combined with HBV.
Innovation Solution
Development of a compound of Formula (I) or its pharmaceutically acceptable salt, which is used in pharmaceutical compositions to treat HBV and HDV infections by inhibiting the replication of the viruses, potentially offering a therapeutic solution for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approved drugs are used to treat HBV, then the replication of the HBV virus is slowed down, but the disease is not cured and continues to be a problem due to drawbacks associated with each approved drug
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of antiviral compounds through various substitutions at different positions (R1-R10 groups) to optimize the balance between antiviral effectiveness and reduction of harmful side effects associated with existing drugs
2Reliability
If current treatments are used for HDV infection, then the replication is suppressed, but there is no cure or vaccine available leading to severe complications and high fatality rates
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters of the bicyclic compound structure (including different heteroatoms, ring sizes, and substituent groups) to develop compounds with enhanced therapeutic efficacy against HDV while reducing the risk of severe complications and fatality
Data Source
AI summary
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.